ERBB2 and neoplasm: In the present work, we demonstrated that anti-HER2 vaccination using the M13 bacteriophage platform induces a significant anti-HER2 antibody response and controls the tumor growth in a breast cancer preclinical model tolerant to human HER2 self-antigen.